Biomarkers of inclusion body myositis

Current Opinion in Rheumatology

Volumn 25, Issue 6, 2013, Pages 753-762

  Greenberg, Steven A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Autoantibodies; Cytoplasmic 50 nucleotidase; Inclusion body myositis; Nucleic acid metabolism

Indexed keywords

5' NUCLEOTIDASE; AMYLOID BETA PROTEIN; ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN P62; RIBONUCLEOPROTEIN; SMI 31 ANTIBODY; TAR DNA BINDING PROTEIN; UNCLASSIFIED DRUG;

AUTOIMMUNITY; CELL VACUOLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; ELECTRON MICROSCOPY; FLUORESCENCE MICROSCOPY; HUMAN; IMMUNOREACTIVITY; INCLUSION BODY MYOSITIS; MEASUREMENT; MUSCLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEIC ACID METABOLISM; PRIORITY JOURNAL; PROGNOSIS; PROTEIN HOMEOSTASIS; REVIEW; SENSITIVITY AND SPECIFICITY;

5'-NUCLEOTIDASE; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; HUMANS; MUSCLE, SKELETAL; MYOSITIS, INCLUSION BODY;

EID: 84885207085     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/01.bor.0000434665.75998.f5     Document Type: Review

References (52)

1. Chou SM. Myxovirus-like structures in a case of human chronic polymyositis. Science 1967; 158:1453-1455
2. Carpenter S, Karpati G, Heller I, Eisen A. Inclusion body myositis: A distinct variety of idiopathic inflammatory myopathy. Neurology 1978; 28: 8-17
3. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69:89-95
4. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984; 16:193-208
5. Mendell JR, Sahenk Z, Gales T, Paul L. Amyloid filaments in inclusion body myositis: Novel findings provide insight into nature of filaments. Arch Neurol 1991; 48:1229-1234
6. Askanas V, Engel WK, Alvarez RB. Light and electron microscopic localization of beta-Amyloid protein in muscle biopsies of patients with inclusion-body myositis. Am J Pathol 1992; 141:31-36
7. Banwell BL, Engel AG. AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis. Neurology 2000; 54:1033-1041
8. Weihl CC, Temiz P, Miller SE, et al. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry 2008; 79:1186-1189
9. Salajegheh M, Pinkus JL, Taylor JP, et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve 2009; 40: 19-31
10. Mirabella M, Alvarez RB, Bilak M, et al. Difference in expression of phosphorylated tau epitopes between sporadic inclusion-body myositis and hereditary inclusion-body myopathies. J Neuropathol Exp Neurol 1996; 55:774-786
11. Nogalska A, Terracciano C, D'Agostino C, et al. p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis. Acta Neuropathol 2009; 118: 407-413
12. Weihl CC, Pestronk A. Sporadic inclusion body myositis: Possible pathogenesis inferred from biomarkers. Curr Opin Neurol 2010; 23:482-488
13. Askanas V, Engel WK, Nogalska A. Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis. J Neuropathol Exp Neurol 2012; 71:680-693
14. Lotz BP, Engel AG, Nishino H, et al. Inclusion body myositis: Observations in 40 patients. Brain 1989; 112 (Pt 3):727-747
15. Greenberg SA, Pinkus JL, Amato AA. Nuclear membrane proteins are present within rimmed vacuoles in inclusion-body myositis. Muscle Nerve 2006; 34:406-416
16. Nakano S, Shinde A, Fujita K, et al. Histone H1 is released from myonuclei and present in rimmed vacuoles with DNA in inclusion body myositis. Neuromuscul Disord 2008; 18:27-33
17. Nishii M, Nakano S, Nakamura S, et al. Myonuclear breakdown in sporadic inclusion body myositis is accompanied by DNA double strand breaks. Neuromuscul Disord 2011; 21:345-352
18. Nalbantoglu J, Karpati G, Carpenter S. Conspicuous accumulation of a singlestranded DNA binding protein in skeletal muscle fibers in inclusion body myositis. Am J Pathol 1994; 144:874-882
19. Dubourg O, Wanschitz J, Maisonobe T, et al. Diagnostic value of markers of muscle degeneration in sporadic inclusion body myositis. Acta Myol 2011; 30:103-108
20. Olive M, Janue A, Moreno D, et al. TAR DNA-Binding protein 43 accumulation in protein aggregate myopathies. J Neuropathol Exp Neurol 2009; 68:262-273
21. Kusters B, van Hoeve BJ, Schelhaas HJ, et al. TDP-43 accumulation is common in myopathies with rimmed vacuoles. Acta Neuropathol 2009; 117:209-211
22. Temiz P, Weihl CC, Pestronk A. Inflammatory myopathies with mitochondrial pathology and protein aggregates. J Neurol Sci 2009; 278:25-29
23. .Kim HJ, Kim NC, Wang YD, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 2013; 495:467-473
24. .Hackman P, Sarparanta J, Lehtinen S, et al. Welander distal myopathy is caused by a mutation in the RNA-binding protein TIA1. Ann Neurol 2013; 73:500-509; Epub ahead of print
25. Buratti E, Brindisi A, Giombi M, et al. TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-Terminal tail: An important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J Biol Chem 2005; 280:37572-37584
26. Liu-Yesucevitz L, Bilgutay A, Zhang YJ, et al. Tar DNA binding protein-43 (TDP-43) associates with stress granules: Analysis of cultured cells and pathological brain tissue. PLoS One 2010; 5:e13250
27. Brais B, Bouchard JP, Xie YG, et al. ShortGCGexpansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet 1998; 18:164-167
28. Spuler S, Engel AG. SMI-31 immunoreactivity in inclusion body myositis. Ann Neurol 1997; 42:815
29. Salajegheh M, Pinkus JL, Nazareno R, et al. Nature of 'Tau' immunoreactivity in normal myonuclei and inclusion body myositis. Muscle Nerve 2009; 40:520-528
30. van der Meulen MF, Hoogendijk JE, Moons KG, et al. Rimmed vacuoles and the added value of SMI-31 staining in diagnosing sporadic inclusion body myositis. Neuromuscul Disord 2001; 11:447-451
31. Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995; 38:705-713
32. Badrising UA, Maat-Schieman M, van Duinen SG, et al. Epidemiology of inclusion body myositis in the Netherlands: A nationwide study. Neurology 2000; 55:1385-1387
33. Hilton-Jones D, Miller A, Parton M, et al. Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008. Neuromuscul Disord 2010; 20:142-147
34. Benveniste O, Hilton-Jones D. International Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on 29 May 2009. Neuromuscul Disord 2010; 20:414-421
35. ENMC 2011 Workshop 'Inclusion Body Myositis'. http://www.enmc.org/ workshops/workshop-reports/inclusion-body-myositis
36. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008; 70:418-424
37. Prayson RA. Diagnostic yield associated with multiple simultaneous skeletal muscle biopsies. Am J Clin Pathol 2006; 126:843-848
38. Blume G, Pestronk A, Frank B, Johns DR. Polymyositis with cytochrome oxidase negative muscle fibres. Early quadriceps weakness and poor response to immunosuppressive therapy. Brain 1997; 120 (Pt 1):39-45
39. Verschuuren JJ, Badrising UA, Wintzen AR, et al. Inclusion Body Myositis. In: Emery AEH, editor. Diagnostic Criteria for Neuromuscular Disorders. Royal Society of Medicine Press, European Neuromuscular Centre; 1997. pp. 81-84.; http://ibmmyositis.com/emery81.pdf. Accessed on March 16, 2013
40. Salajegheh M, Kong SW, Pinkus JL, et al. Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol 2010; 67:53-63
41. Parker KC, Kong SW, Walsh RJ, et al. Fast-Twitch sarcomeric and glycolytic enzyme protein loss in inclusion body myositis. Muscle Nerve 2009; 39:739-753
42. Sekul EA, Chow C, Dalakas MC. Magnetic resonance imaging of the forearm as a diagnostic aid in patients with sporadic inclusion body myositis. Neurology 1997; 48:863-866
43. Phillips BA, Cala LA, Thickbroom GW, et al. Patterns of muscle involvement in inclusion body myositis: Clinical and magnetic resonance imaging study. Muscle Nerve 2001; 24:1526-1534
44. Dion E, Cherin P, Payan C, et al. Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis. J Rheumatol 2002; 29:1897-1906
45. Cox FM, Reijnierse M, van Rijswijk CS, et al. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology (Oxford) 2011; 50:1153-1161
46. Greenberg SA, Sanoudou D, Haslett JN, et al. Molecular profiles of inflammatory myopathies. Neurology 2002; 59:1170-1182
47. Greenberg SA, Bradshaw EM, Pinkus JL, et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 2005; 65:1782-1787
48. Bradshaw EM, Orihuela A, McArdel SL, et al. A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol 2007; 178:547-556
49. Greenberg SA. A gene expression approach to study perturbed pathways in myositis. Curr Opin Rheumatol 2007; 19:536-541
50. Salajegheh M, Lam T, Greenberg SA. Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. PLoS One 2011; 6:e20266
51. .Larman HB, Salajegheh M, Nazareno R, et al. Cytosolic 50-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013; 73:408-418
52. .Pluk H, van Hoeve BJ, van Dooren SH, et al. Autoantibodies to cytosolic 50-nucleotidase IA in inclusion body myositis. Ann Neurol 2013; 73:397-407